ClinicalTrials.gg
CompletedNCT01147315ORNUpdated Apr 6, 2018

ORN Study: Curative Treatment of Osteoradionecrosis (ORN) With Hybrid Bone Substitution

An interventional study of Hybrid bone substitution in Mandible and Osteoradionecrosis, sponsored by Nantes University Hospital. Completed at 2 sites in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-04-06.

Sponsored by Nantes University Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The main objective of the study is the cure of osteoradionecrosis (ORN) at 12 months.

02

Conditions studied

  • Mandible
  • Osteoradionecrosis

Browse trials for

Keywords

  • mandibular osteoradionecrosis
  • hybrid bone substitution
  • calcium-phosphate ceramic biomaterial
  • autologous bone marrow
03

In context

Osteoradionecrosis

24 studies on the registry are indexed under Osteoradionecrosis; 8 are open to participants now.

This study's enrollment of 13 is below the median of 60 across 13 interventional studies indexed under Osteoradionecrosis.

Browse Osteoradionecrosis studies →

Lead sponsor

Nantes University Hospital is the lead sponsor of 839 studies on the registry; 195 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (between 18 and 75 years) affiliated with an appropriate social security system, diagnosed as suffering from symptomatic ORN, radiologically confirmed, for which surgery is indicated
  • Presence maximum of 2 outbreaks of ORN
  • Oncological remission of the original tumor site for 1 year and for 3 years if the ORN is in the contact or close to the initial tumoral site
  • performance status 0, 1 or 2
  • ORN symptomatic accessible to the conservation of at least one cortical mandibular basilar
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Oncological treatment
  • Haematologic background
  • Current bone necrosis consecutive or concurrent to taking bisphosphonates
  • Extension of ORN does not allow the retention of a mandibular rod (bicortical form)
  • Presence of fracture complicating ORN
  • Bisphosphonates during the last year
  • to the removal of iliac or sternum bone marrow
  • Contraindication for general anesthesia
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Hybrid bone substitution

    Hybrid bone substitution with calcium-phosphate ceramic biomaterial and autologous bone marrow

    Procedure: Hybrid bone substitution

Interventions

  • ProcedureHybrid bone substitution

    The patient will be treated by hybrid bone substitution with calcium-phosphate ceramic biomaterial and autologous bone marrow after necrosis exeresis

06

What researchers measure

Primary outcomes

  1. The cure of ORN

    Time frame: 12 months

Secondary outcomes

  1. Evaluation of post operative pain at mandibular and bone marrow sampling site

  2. Quality of life

  3. Possibility of secondary dental prosthetic devices

  4. CT semiology description of the treated area

  5. Bone regeneration

    Bone regeneration: kinetics of formation of new bone and biomaterial resorption

  6. Number of hospital days

  7. Safety of hybrid bone substitution

07

Study locations

2 sites
  • Nantes University Hospital
    Nantes, 44093, France
  • Rennes University Hospital
    Rennes, 35000, France
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Nov 2016 and a completion of Nov 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2010
First posted
Jun 22, 2010
Start
Nov 18, 2009
Primary completionActual
Nov 16, 2016
CompletionActual
Nov 16, 2016
Last update
Apr 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01147315
Responsible party
Sponsor
First posted
Jun 22, 2010
Start date
Nov 18, 2009
Primary completion
Nov 16, 2016
Completion
Nov 16, 2016
Last update
Apr 6, 2018

Study contacts

Olivier Malard, Pr
principal investigator · Nantes University Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion